No PBS listing for HIV prevention pill
A HIV prevention drug won't be taxpayer-subsidised after it failed to receive recommendation to the Pharmaceutical Benefits Scheme.
An application to list Truvada - a once-daily pill which costs around $750 a month and aimed at preventing HIV transmission - was rejected on Friday by the Pharmaceutical Benefits Advisory Committee.
The Department Of Health said the price requested by the maker, Gilead Sciences, was far too high and it was not feasible to limit the drug to a smaller, high-risk subset of the whole "at risk" population.
"The PBAC would welcome another submission ... addressing its concerns about cost effectiveness and the appropriate eligible population," a spokeswoman said in a statement to AAP.
The Australian Federation of AIDS Organisations said it was disappointed with the decision, urging Gilead to submit another application.
"People are needlessly getting HIV while we wait for access to this prevention pill," chief executive Darryl O'Donnell said.
Share a tip-off, video or photo with us
Most viewed in Australia
Australian woman who died after falling from cliff near Bali was Queensland ecologist
PM ‘stunned’ over Pauline Hanson’s attack on his late mother
Police called to One Nation event after clash between passer-by and volunteer
Six years ago, Australia had a $38 billion early super experiment. It didn’t go to plan
